Barclays
MRNA icon

Barclays’s Moderna MRNA Stock Holding History

Barclays’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,000
Closed -$965K – 5526
2026
Q1 		$965K Sell
19,000
-572,200
-97% -$26.7M ﹤0.01% 2785
2025
Q4 		$17.4M Buy
591,200
+419,000
+243% +$11.4M ﹤0.01% 1320
2025
Q3 		$4.45M Buy
172,200
+171,000
+14,250% +$4.77M ﹤0.01% 2298
2025
Q2 		$33.1K Sell
1,200
-153,000
-99% -$4.03M ﹤0.01% 4767
2025
Q1 		$4.37M Buy
154,200
+69,200
+81% +$2.46M ﹤0.01% 2012
2024
Q4 		$3.53M Buy
85,000
+65,000
+325% +$3.11M ﹤0.01% 2458
2024
Q3 		$1.34M Sell
20,000
-252,700
-93% -$23.2M ﹤0.01% 3156
2024
Q2 		$32.4M Buy
272,700
+252,700
+1,264% +$32M 0.01% 766
2024
Q1 		$2.13M Sell
20,000
-138,700
-87% -$14M ﹤0.01% 2507
2023
Q4 		$15.8M Buy
+158,700
New +$13.3M 0.01% 1183
2023
Q2 		– Sell
-265,100
Closed -$40.7M – 4889
2023
Q1 		$40.7M Sell
265,100
-631,700
-70% -$104M 0.02% 551
2022
Q4 		$161M Buy
+896,800
New +$147M 0.07% 196
2022
Q3 		– Sell
-544,700
Closed -$77.8M – 5013
2022
Q2 		$77.8M Buy
+544,700
New +$77.9M 0.05% 268

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Barclays's MRNA Position: Q2 2026 in Review

Barclays increased its Moderna (MRNA) stake by 11% in Q2 2026, buying an estimated $5.32M and bringing the position to 1,035,126 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #602.

Barclays first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $839M in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Barclays held 1,035,126 shares of Moderna worth $72.5M as of Q2 2026.
  • Barclays bought 102,857 Moderna shares in Q2 2026, an estimated $5.32M.
  • Moderna made up 0.01% of Barclays's portfolio in Q2 2026, its #602 holding.
  • Barclays first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
  • Barclays's Moderna position peaked at $839M in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.